Archives: Published Articles

cGMP Training for Data Integrity

Integrating Data Integrity Into Annual cGMP Training

FDA’s guidance on data integrity reinforces the importance of ensuring personnel understand how to identify and prevent data integrity issues. But organizations do not necessarily need to create an entirely new training program to address these expectations. Instead, data integrity principles can be incorporated into existing cGMP, good documentation practices (GDP), and investigations and CAPA training.

 

This article explores how companies can use their existing quality systems to strengthen data integrity awareness. Key areas include proper documentation practices, correcting errors, timely signatures, electronic signature controls, password protection, and understanding the responsibilities of operators, verifiers, and reviewers.

 

The article also highlights the role of investigations, CAPAs, internal audits, and SOPs in maintaining reliable records throughout the manufacturing process. By reinforcing data integrity concepts through routine training and quality processes, organizations can help ensure that both paper and electronic records accurately and reliably support product quality and patient safety.

 

Read the full article published by PharmTech:

cGMP Training for Data Integrity

International Medical Device Regulatory

Lisa L. Michels, General Counsel and regulatory affairs expert at Regulatory Compliance Associates® Inc., discusses how the global medical device regulatory landscape is impacted by international law.

 

The global medical device regulatory landscape is constantly evolving as governing bodies and/or agencies worldwide continue their efforts to harmonize and streamline rules. Over the last several years, many of these regulatory bodies have joined forces to ensure consistency in the interpretation, application, and implementation of relevant medtech regulations and globally recognized consensus standards.

 

Regulatory Submission

 

While such efforts have considerably improved the product registration process overseas, harmonization in some cases has made it difficult for some device firms to stay abreast of the planet’s evolving regulatory landscape. To remain competitive in this challenging environment, medtech companies stay ahead of the competition by proactively planning for new and/or changing global regulations. This helps agile organizations successfully launch existing, modified, or novel products in new target markets quickly. 

 

Medical Device Registration

 

Most companies want their products to be registered in as many global markets as possible, but this lofty goal introduces certain regulatory challenges. From a general business perspective, global product registration in numerous foreign markets obviously makes sense.

 

Companies possessing the legal authority to sell product(s) in certain regions where competitors are not authorized to do so often distinguishes those organizations as leaders or industry trailblazers. This approach is not always logical or practical, however.

 

Regulatory Pathway

 

Product registration should be based on a proactive strategic regulatory analysis. Understanding the available regulatory pathway options can help properly determine whether registration in a particular market. Ultimately, the team is challenges with the regions that make sense for the product and business as a whole.

 

The most common international medical device registration challenges are primarily based on the following considerations:

  • Understanding and applying country-specific medical device regulations across global markets
  • Timely implementation of country-specific medical device regulations in target markets
  • Costs associated with global product registration(s), which may include (but are not limited to) in-country agent representation, in-country product testing, and in-country collection of clinical data
  • Excessive delays and/or long lead times for regulatory reviews needed for global product registration(s) in target markets

 

Device Classification

 

These challenges are much easier to manage when they are properly assessed well before starting the product registration processes in certain global markets. Based on the device classification and type of product, there may be more (or less stringent) requirements that must be achieved in specific countries.

 

The risk level of the product and the existence of similar approved products in a particular market can complicate the product registration process in certain countries.

 

Medtech Programs

 

Many medtech companies typically tend to focus their medical device product registration efforts on seven (7) primary global markets: the United States, Canada, European Union (EU), Australia, Brazil, China, and Japan. Due to ongoing harmonization efforts, these countries are working together to streamline the registration processes and improve their consistency. 

 

Depending on the company’s overall product launch strategy, device registration in emerging markets has become common in recent years. In certain cases, product registration may be less challenging in these markets because regulations have not yet been fully developed.

 

Pre-Clinical Testing

 

The applicable medical device regulations in target markets each pose their own product registration challenges. Therefore, it is imperative that companies plan for all target market requirements early in the product development process—ideally at the idea stage.

Understanding and preparing for the hurdles associated with pre-clinical testing, clinical testing, performance testing, safety testing, labeling, and compliance with harmonized standards, can help companies overcome possible challenges with the product registration process in each potential target market.

 

regulatory compliance
 
Table: Summary Regulatory Requirements for Global Medical Device Registration in the Primary Target Markets
 
 

Regulatory Compliance

 

Achieving product registration compliance in each target market may seem like a daunting endeavor, but it’s not truly as complicated as it sounds. There are many similarities between the various regulations, as outlined in the table at right. Although the table represents only a subset of requirements, the country-specific mandates applicable to product type in each of the target markets must be carefully reviewed and assessed.

 

The most effective method to accomplish this task is to prepare a global regulatory strategy for the product(s), which may ultimately be used as a gauge to determine the likelihood of successfully launching a device in a particular market.

 

Regulatory Strategy

 

A global regulatory strategy is a documented analysis that defines the overall business objectives and requirements necessary for foreign product registration. A regulatory plan, on the other hand, is a comprehensive report based on the foundational regulatory strategy that outlines all product- and country-specific registration mandates in particular markets. 

 

The regulatory strategy and plan may be separate stand-alone documents or combined into a single global strategy and planning file. Regardless of format, however, their purpose is the same—to proactively document and plan for the implementation of applicable regulatory requirements associated with specific products in each target market.

 

Regulatory Audit

 

Keep in mind that these regulatory strategy and planning document(s) are not static. They must be updated and revised accordingly when changes are made either to the product itself or to the device’s launch strategy. A revision would be required, for example, if target markets are added or removed from the launch strategy. Any regulatory body will want to understand the risks made to existing products and regulations (particularly when new rules are introduced that can significantly affect or completely alter product registration mandates).

 

The format of the regulatory strategy and planning document ultimately depends on the company. Some organizations encourage the use of a specific format or template to document the regulatory strategy and/or plan. Other firms are more liberal about format.

 

Medical Device Regulatory

 

Fundamentally though, the setup of the regulatory strategy and planning document is not as important as the goal: To initiate and maintain robust, proactive, regulatory planning efforts as early as possible, and to effectively monitor any changes in the scope to avoid unexpected and costly delays. The key elements of a global regulatory strategy and planning document are also outlined in the table. 

 

Medical Device Global Regulatory Strategy and Planning Document

 

Detailed Product Summary

  • Detailed description of the product including its accessories, components, and software (if applicable)
  • Describe the product requirements, including technological/functional/performance/clinical requirements of the product (e.g., what the product does and how it works/mode of operation)
  • Indications for use/intended use
  • Target population
  • Labeling requirements
  • All proposed marketing claims and requirements for claim substantiation
  • Risk level/product classification/applicable product codes
  • Predicate(s) and/or similar products on the market in each target country

 

Governing Regulatory Body and/or Agency in Each Target Market

  • Planned target markets for product launch
  • Applicable laws, regulations, standards, and relevant guidance for the product
  • Analysis of harmonized requirements and standards for the product across all target markets
  • Reimbursement requirements and other country-specific considerations

 

Proposed Regulatory Pathway and Product Registration Requirements in Each Target Market

  • Regulatory submission/product registration requirements, including all applicable product testing requirements (e.g., pre-clinical testing, animal testing, clinical testing, performance testing, safety testing, etc.)
  • Timeline to obtain clearance/approval
  • Costs associated with global product registration
  • Required resources (internal/external)
  • Pre-market submission/early interaction, discussion, or consultation with governing regulatory agency or authority regarding product and proposed regulatory pathway

 

General Requirements for Product Registration in Each Target Market

  • Implementation of a Quality Management System (QMS) compliant with applicable regulations and/or standards
  • QMS audit/inspection of manufacturing facilities by the regulatory agency

 

Country-Specific Requirements for Product Registration in Each Target Market

  • Appointment of an in-country, local agent/representative/sponsor/distributor to manage the product registration on behalf of a foreign manufacturer
  • In-country product testing requirements and product samples
  • In-country clinical trial/data collection requirements
  • Product registries/databases
  • Labeling requirements
  • Language translations for labeling [e.g., instructions for use (IFU), operator or user manual, labels, etc.]

 

Other information as applicable for the specific type of product

 

Recommendations for Successful Navigation

 

The key to successfully navigating through the regulatory challenges of global product registration in the international marketplace starts and ends with diligent and proactive planning.

Product registration efforts should focus on markets where companies can leverage device submission documentation for previously approved applications. If, for example, a company has U.S. Food and Drug Administration clearance and/or CE mark approval for a product, it is often easier to register that exact device in another global market that recognizes the same (or similar) harmonized requirements and standards.

 

Companies should ensure their products are tested and comply with globally recognized consensus standards. A sampling of medical devices standards recognized in many international markets include:

 

  • EN 1041:2008—Information supplied by the manufacturer of medical devices
  • EN ISO 13485:2012—Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003)
  • EN ISO 14155:2011—Clinical investigation of medical devices for human subjects – Good clinical practice (ISO 14155:2011)
  • EN ISO 14971:2012—Medical devices – Application of risk management to medical devices (ISO 14971:2007, Corrected version 2007-10-01)
  • EN 60601-1:2006—Medical electrical equipment—Part 1: General requirements for basic safety and essential performance
  • EN 60601-1-2:2007—Medical electrical equipment—Part 1-2: General requirements for basic safety and essential performance – Collateral standard: Electromagnetic
  • EN 60601-1-6:2007—Medical electrical equipment—Part 1-6: General requirements for basic safety and essential performance – Collateral Standard: Usability
  • EN 62304:2006—Medical device software – Software life-cycle processes

 

A comprehensive global regulatory strategy and planning document must be prepared that clearly identifies all county-specific requirements necessary for successful product registration in each target market. In addition, companies should set realistic and attainable goals for timely product launches only in the markets that align with their overall global business strategy. Commercialization will only be successful if the product is a logical fit for the chosen market.

 

Perhaps most importantly, medtech firms must not register a product in a certain market simply because they can do so. Rather, they should make strategic and informed regulatory decisions about their product launch plans so they can avoid the most common regulatory challenges impacting this highly competitive industry. 

 

To begin the Regulatory Compliance Associates® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

 

Strategic Lifecycle Approach to Medical Device Regulation

By Seyed Khorashahi, MSc, and Mark Agostino, MSc

 

 

The purpose of this article is to highlight new facets of EU Medical Device Regulation (MDR) in the medical device industry. The article contains references to both MDR legal articles and recommendations that will challenge organizations to take a more holistic viewpoint of their products, resources, and regulatory toolkit to be compliant in the EU.

Introduction

medical device regulationThe application date of 2017/745 MDR1 is 26 May 2021, when it will officially supersede the 93/42/EC Medical Device Directive (MDD) that came into effect in 1993. Medical device companies that market their products in the EU are now responsible for meeting new, comprehensive requirements and compliance expectations during the entire lifecycle of their products.

 

Every medical device manufacturer, importer, and distributor who wants to continue marketing their product into the EU or initiate business in the EU after 26 May 2021 will be responsible for MDR compliance.2 This is a significant change for many different organizations around the world. The rigor required by EU notified bodies will affect the time and resources companies need to become Medical Device Regulation compliant based on the risk of the device.

 

Have questions about MDR Implementation? Contact Us Now →

 

Lifecycle management

 

Lifecycle management in the medical device industry is constantly evolving because of new legal regulations; the complex risks associated with modern technology; the more advanced levels of oversight for legacy products; and increased exposure of development cycle process gaps. These changes present a challenge for notified bodies to become accredited under the new regulations, resulting in a smaller number of MDR-designated notified bodies.

 

Consequently, the timelines for conformity assessments of quality system and technical documentation have also increased. This directly challenges organizations to develop more proactive lifecycle strategies when preparing to obtain their CE mark,3 the formal sign of conformity received from a notified body indicating that the device has met both quality system and technical documentation requirements of the EU Medical Device Regulation and can be placed in the EU market.

 

Product Lifecycle

 

The foundation of MDR legislation is based on historical product lifecycle issues and quality concerns. These new legislative parameters are designed to drive an increase in both regulatory education and corporate accountability across the entire industry.4

 

Economic operators in the supply chain become responsible for reporting complaints to the device manufacturer, which includes registering medical devices distributed across their supply chain to healthcare providers. Notified bodies also now have a legal responsibility based on product lifecycle quality control and can be held liable based on the manufacturer device class.

 

Postmarket surveillance

 

Postmarket surveillance (PMS), vigilance, and market surveillance are covered in articles 83-100 of the MDR, and address/cover the following:5

 

  • Postmarket surveillance system of the manufacturer.
  • Postmarket surveillance plan.
  • Periodic safety update report.
  • Reporting of serious incidents and field safety corrective actions.
  • Trend reporting.

PMS and vigilance activities are meant to drive awareness and initiate field corrective actions addressing field-related issues. In addition, these activities help assure sufficient knowledge of an evolving device technology landscape to assess the benefit-risk profile for a medical device.

 

PMS as described in the articles 83-86 is designed to increase the accountability and reporting visibility of data included in clinical evidence plans and reports. Vigilance, as described in the articles 87-92, tend to be more reactive and deals with reporting of serious incidents and field safety corrective actions.

 

An effective PMS program provides:

 

  • Real-world experience using a broad spectrum of physicians and patients, outside the confines of pre- and postmarket trial(s);
  • Early warning signs of problems by continuously and systematically collecting and evaluating data;
  • Incentives for early corrective action, such as initiating corrective and preventive actions or a device recall;
  • Increased compliance with relevant legislation; and
  • Additional value beyond compliance (e.g., usability).

 

Vigilance

 

Vigilance defines the type of incidents that medical device companies report, which can affect the long-term risk associated with both the device class and timelines for recertification. Guidance documents from the Medical Device Coordination Group can clarify the interpretation of the new regulation and increase understanding of the planning and resources needed from the manufacturer based on these new risk qualifications.

 

Corrective Action

 

Manufacturers will need to be agile enough to react to the data analysis and quickly address necessary corrective actions. Having a cross-functional triage process driven by risk management can help the regulatory team make appropriate risk-based decisions. Through the analysis, the benefit becomes a deeper understanding of periodic safety, complaints, literature, and overall performance of the device.

 

One should also consider need for oversight of current products already sold in the marketplace. Reporting must be approved by the person responsible for regulatory compliance, and clinical approval relies on the expertise of the individual creating the reporting.

 

Risk Management

 

Risk management processes to gather information from the field will help address the severity of new issues or recurrence of existing issues. Manufacturers and organizations will now have accountability to remedy issues and have accountability if recurring or existing issues are not resolved. Senior level executives must drive accountability throughout the organization to increase the level of accountability by the entire regulatory and quality assurance team.

 

Internal Audit

 

Many medical device companies are learning as they go while still conducting their necessary daily business. They should also consider how much new accountability is needed across their respective enterprises. There are new educational resources that can help companies understand the regulation and resulting accountability gaps, but a greater level of investigation will be achieved primarily through a detailed internal audit.

 

Unique Device Identifier (UDI)

 

The incorporation of unique device identifiers (UDIs) in the Medical Device Regulation will help with the traceability of devices, similar to the US Food and Drug Administration UDIs, and will enhance the effectiveness of PMS and vigilance. The UDI requirements define a more targeted approach to field safety corrective actions and supply chain monitoring, including the prevention of potential counterfeit products. UDI activities comprise of UDI registration, obligation to place UDI on devices, and UDI data submission.

 

The implementation of MDR UDI has different timelines, depending on the device classifications, but all devices need to complete the UDI registration to obtain a basic UDI device identifier (DI) from one of the issuing entities, such as GS1 or the Health Industry Business Communications Council.

 

EUDAMED

 

The basic UDI-DI is the primary identifier referenced in the technical documentation and the main key for records in EUDAMED, the European database for on medical devices. The obligation to place UDI on devices and UDI data submission will be required on 26 May 2021 for Class III and implantable Class IIb devices; on 26 May 2023 for Class IIa and non-implantable Class IIb devices; and 26 May 2025 for all Class I devices.

 

In addition, there should be a strategy in place for legacy devices if the new elements of MDR regulation are to be completed. The UDI label design for packaging configurations should be considered to ensure compliance with the increased regulatory expectations in the delivery channel.

 

Harmonization

 

The potential for harmonization within the medical device industry is increasing as the industry moves closer to a universal label based on requirements from multiple countries and regulatory bodies. Translations may differ slightly between countries because of on language variations, but the device tracking process should be easier once the label is finalized and regulatory approval is given.

 

Traceability and market surveillance will invite new analyses beyond the design and application of the label.

 

Regulatory Submission

 

The requirements notified bodies have to meet under the EU MDR are extensive and are listed on Annex VII of the EU MDR.6 With the new regulation, there will be fewer notified bodies than the number of MDD-designated, so companies should find and engage with their notified bodies as early as possible in the regulatory submission process. MDD legislation allowed for a less stringent certification process for lower-risk classes of devices.

 

Compliance Standards

 

With new MDR compliance standards now in place, medical devices that were previously in one class may move into another level of risk. This may increase the accountability needed for select product lines and application use cases.

 

Be deliberate about reviewing the product portfolio and recognize there may be changes needed in the expertise within the regulatory team. Employees could be cross-trained over time to facilitate compliance within the new MDR process and work with the different notified bodies.

 

In addition, not all notified bodies have the technical capabilities for performing conformity assessment for all types of devices and technologies, which may also present challenges and slow down the assessment process.7 

 

Product Classification

 

If a product’s classification requires involvement of a notified body for conformity assessment, it is worth noting that successful teams often engage early with their notified body to align with their expectations based on the risk level of their products.

 

Under MDD, notified bodies also had a consultative opportunity to counsel companies, but that will no longer be available to medical device companies. Without this advisory input from the notified body, companies are at risk of legal liabilities as they try to meet the MDR requirements on their own.

 

Notified Body

 

It is therefore important they address ways to compensate for no longer having advisory input from the notified body, for example, by working with a consultant who is not associated with the notified bodies. In addition, the regulatory team should identify the professional skill sets needed for engaging with a notified body and develop educational strategies for training employees who will be working with a notified body for the first time.

 

State-of-the-Art Design

 

Manufacturers commonly have questions during postmarket surveillance about understanding the difference between what is, and what is not, state-of the-art in design. For the sake of clarity, “state of the art” is intended to define new products that have been developed and approved for sale. This is unique to devices that are already in the field and have some form of legacy CE marking. A new device cannot be considered state of the art until this updated regulatory approval is given.

 

The term “state of the art” is a widely used term but was specifically defined within the medical device context in ISO/IEC Guide 63:2019,8 which says state of the art is the “developed stage of technical capability at a given time as regards products, processes, and services, based on the relevant consolidated findings of science, technology, and experience.”

 

Clinical Evaluation

 

EU MDR mentions the term “state of the art” 12 times but does not define it. MEDDEV’s Clinical Evaluation document9 describes it as the current knowledge/state of the art in the corresponding medical field, such as applicable standards and guidance documents, information relating to the medical condition managed with the device and its natural course, benchmark devices, other devices and medical alternatives available to the target population.

 

Risk Profile

 

As new technologies build upon existing platforms, the intent of the term is to ensure that a proposed device technology is considering the benefits and risks of the similar existing devices that are on the market. The objective being driven by EU MDR and notified bodies is that a proposed device technology meets, at a minimum, the current benefit and risk profile or is able to improve upon the existing profile for similar devices.

 

Software as Medical Device (SaMD)

 

The technology landscape for medical devices is quickly evolving as new devices such as software as a medical device, wearables, and combination products come to market. The challenge for manufacturers is to be aware of the benefits and risks related to the device technology under development.

 

Conformity Assessment

 

Demonstrating an understanding of state of the art and incorporating it into the design and development processes will lead to favorable conformity assessment with a notified body. EU MDR raises the bar on the requirements toward having robust postmarket surveillance, vigilance, and clinical evaluation programs. These programs help manufacturers demonstrate to a notified body that their device technology will go to market with an acceptable benefit-risk profile.

 

Clinical Evaluation

 

Clinical evaluation validates the intended use of a medical device and establishes the safety and efficacy in a clinical setting.10 A critical facet of the MDR is to obtain CE marking through the conformity assessment process. There are unique standards and protocols that have been established and must be followed when developing CE marking for regulatory approval.

 

CEP and CER

 

The Medical Device Regulation has increased the amount of supporting data medical device companies need to provide to with their submissions for approval of a clinical evaluation, which includes monitoring the performance and intended use of a product based on standards of efficacy. Two of the critical steps of Medical Device Regulation include generating a clinical evaluation plan (CEP) and clinical evaluation report (CER).

 

Clinical Evaluation Plan (CEP)

 

The CEP presents the rationale, objectives, design, methodology, monitoring, statistical considerations, organization, and conduct of a clinical investigation. It is the blueprint for demonstrating how the device will meet clinical and performance claims made in the intended purpose throughout its lifecycle. The Medical Device Coordination Group has not published a template for CEP, although it has one for the clinical evaluation assessment report and provides guidance on templates for the PMCF evaluation report and PMCF plan.

 

The CEP is tightly coupled with PMS, risk management, and usability of the device. As an example, if the usability aspect of a product fails to perform during the clinical investigation as anticipated, then the regulatory or clinical team may incorporate those usability failures as part of the clinical evaluation plan to inform later PMS, risk management, and usability considerations. Other inputs for the CEP include, but are not limited to, sterility and biocompatibility.

 

Clinical Evaluation Report (CER)

 

The CEP will also provide a roadmap for creating the CER, which would be submitted to a notified body or competent authority as needed to communicate the overall benefit-risk profile for a medical device. The CER is more detailed and includes:

 

  • Intended use, device description, device classification, clinical evaluation plan, common specifications, if applicable, applicable standards, product equivalence, and state of the art;
  • Clinical literature review, clinical investigations, and related documentation;
  • PMS, postmarket clinical follow-up (PMCF), and the plan for updates and reporting;
  • Labeling, instructions for use, summary of safety and clinical performance (nonclinical and clinical); and
  • Summary of all available data and conclusions.

The  items provided above incorporate the 4 stages for creating a CER, as outlined by MEDDEV.9 Because the report is submitted to a notified body or competent authority it would require the integration and coordination of a cross-functional regulatory and/or clinical team to capture the full range of necessary information. As such, the report is an important tool for communicating an understanding of the device among regulators.
 

Postmarket Surveillance

 

The purpose of PMS is to continuously verify the benefits of medical devices throughout the product lifecycle and identify previously unknown risks through observation and analysis of real-world, daily practical usage. If PMS observations suggest changes might be needed in the clinical evaluation plan or report, then PMCF studies must be done to obtain supporting data for updating and revising the CEP/CER to reflect the new findings.

 

Be proactive in defining how the regulatory/clinical team will monitor uses of the device for both approved and off-label use cases. Also be prepared to proactively integrate your clinical findings and risk management strategies into a cohesive route to regulatory compliance.

 

Person Responsible for Regulatory Compliance (PRRC)

 

Medical device manufacturers need to have oversight of product development throughout the lifecycle, lifecycle (from design, manufacturing, postmarket surveillance/vigilance activities, and so on.)

 

Manufacturers must have at least one person in the company who is a medical device expert and can be designated as the person responsible for regulatory compliance (PRRC). The PRRC ensures the conformity of the device is appropriately checked; the technical documentation and EU declaration of conformity are written up and kept current; and the PMS and vigilance obligations are met. Micro- and small enterprises are not required to have a PRRC but need to have such a person at their disposal.11

 

Compliance

 

The PRRC is often designated by a company’s senior management, which underscores the level of responsibility of the position and importance of coordinating collaboration across a number of teams to maintain compliance. The position carries significant legal responsibility for the PRRC because the company could hold them accountable for data quality errors that may lead to noncompliance over time.

 

As such, companies are required to have liability insurance in case they are sued by EU citizens who might suffer physical, device-related harm.

 

Summary

 

Given the extent of the changes under the MDR, organizations are being challenged to take a more holistic viewpoint of their products, resources, and regulatory toolkit to maintain product compliance in the EU. Lifecycle management is just one piece of the puzzle to maintaining regulatory compliance. There are unique approaches to lifecycle management under the new Medical Device Regulation that should be considered.

 

Postmarket surveillance helps establish a process for identifying and rectifying issues during the course of the product lifecycle. Notified bodies now have a process to absorb the feedback from clinical evaluations to ensure medical devices being designed and manufactured meet the stated intended use. The UDI makes it significantly easier to prioritize what issues need to be addressed and ensure tracking mechanisms are in place so field corrective actions can be accurately executed.

 

Product Information

 

That is possible because the UDI has specific product information – lot number, date of manufacturing, expiration date, and so on – which can be used to recall products that are defective. These pieces of information are both human and machine readable (the latter, by barcode or radio-frequency identification), which makes it easier to remove a product from the supply chain.

 

Quality Management System 

 

And finally, the quality management system (QMS) is the critical element for the regulatory team to implement and manage a successful PMS strategy.12 This “listening system,” comprised of all the aforementioned elements, provides a company the closed-loop feedback needed from the real-world situations to improve clinical performance.

 

This helps minimize the cost containment of a product recall by recalling only noncompliant devices based on the specific UDI information, which can help device firms align across the supply chain.

 

 

Abbreviations
CEP, clinical evaluation plan; CER, clinical evaluation report; MDD, Medical Device Directive; MDR, [EU] Medical Device Regulation; PMCF, postmarket clinical follow-up; PMS, postmarket surveillance; PRRC, person responsible for regulatory compliance; UDI, unique device identifier; UDI-DI, UDI device identifier.
 
About the authors
Seyed Khorashahi, MSc, is executive vice president of medical devices and chief technical officer at Regulatory Compliance Associates (RCA). 
 
Mark Agostino, MSc, RAPS, is managing director of QARA Biomed and senior medical device good manufacturing practice expert at Redica Systems. His areas of expertise include quality assurance and regulatory affairs for medical device and combination products. He has provided guidance to sponsors and contract service providers on meeting requirement for the design history and technical files for the FDA and under the EU Medical Device Regulation; compliance with ISO 14971:2019; implementing supplier quality processes; conducting internal and external audits; preparing global regulatory submissions; and ensuring compliance to global standards and regulations. Agostino has a master of science degree in biomedical engineering from Worcester Polytechnic Institute, Mass., and an executive MBA from Suffolk University, Boston. He is a member of RAPS and can be reached at [email protected]
 
Citation Khorashahi S, Agostino M. Strategic lifecycle approach to medical device regulation. Regulatory Focus. May 2021. Regulatory Affairs Professionals Society.
 
References
All references were accessed on 24 May 2021. Except for reference 6, 8, and 9, all references are for Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745&qid=1620164088978&from=EN, with page numbers provided for the specific sections.
 

  1. Reg. 2017/745, Articles 1-4:13-20.
  2. Reg. 2017/745, Articles 1-4.
  3. Reg. 2017/745, Articles 19-20:32.
  4. Reg. 2017/745, Articles 25-34:34-40.
  5. Reg. 2017/745, Articles 83-100:71-82.
  6. Reg. 2017/745, Annex VII:123-139.
  7. Reg. 2017/745,  Articles 51-60:49-55.
  8. International Organization of Standardization/International Electrotechnical Commission. Guide to the development and inclusion of aspects of safety in International Standards for medical devices: Terms and definitions [3.18]. https://www.iso.org/obp/ui/#iso:std:iso-iec:guide:63:ed-3:v1:en Dated 2019. Accessed 24 May 2021.
  9. European Commission. Guidelines on medical devices. Clinical evaluation: A guide for manufacturers and notified bodies [Directives 93/42/EEC and 90/385/EEC (MEDDEV 2.7.1 Rev. 4) https://ec.europa.eu/docsroom/documents/17522/attachments/1/translations/en/renditions/native.
  10. Reg. 2017/745, Articles 61-82:55-71.
  11. Reg. 2017/745, Article 15:28.
  12. Reg. 2017/745, Article 10:23-5.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Quality Culture Benefits All

Regulatory Compliance Associates® (RCA) Distinguished Fellow, Susan Schniepp discusses establishing a quality culture from the top of an organization down.

 

Quality culture is a patient-focused approach to quality that is proactive not reactive or procedural, according to Rick Friedman of FDA, in a conference presentation. When an organization is focused on quality, it can detect problems earlier. Further, quality culture helps manufacturers experience fewer deviations, costly remediations and protect its brand, according to Friedman.

 

Highest Quality

 

Creating a quality culture means an investment in quality including organizational structure and actions. Moreover, the highest quality standards include support for all levels of the company and making business decisions. 

 

Top Quality

 

“Companies with good quality cultures usually have transparency and collaboration between departments,” says Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates.  “This is critical when there are problems that impact manufacturing. In addition, companies with a robust culture usually solve the problem faster, which helps them maintain high productivity rates,” she says.

 

Quality Department

 

The quality department in a bio/pharmaceutical company plays a critical, but not exclusive, role when it comes to ensuring that biologics and drugs are safe and effective. The entire organization, however, must be involved in ensuring quality is built-in.

 

“Let’s clear up one issue right away,” says Schniepp. “When we refer to quality culture, we are referring to the culture of the company and not the culture of the quality department. Having an established quality department does not mean a company has a culture of quality.”

 

Regulatory Affairs

 

“In a robust culture, the attention to quality is a responsibility of all employees, not just those who work in the quality department. In a robust quality culture, the quality department is a partner with regulatory affairs and operations, it’s a policing function,” Schniepp stresses.

 

“Quality culture is an all-pervading attitude and sense of purpose in which quality is foremost in everybody’s activities. A quality department is a part of the organization that monitors quality, (e.g., by end-product testing). However, quality cannot be tested into the product. It is inherent, and has to be built in—by design controls,” agrees Chris Moreton, PhD, vice president of pharmaceutical sciences at Finnbrit Consulting.

 

Operations Management

 

According to Friedman, “senior management has a critical ongoing oversight role to ensure suitability of operational design, compliance assurance, and maintenance.” Friedman points to behaviors that can lead to the development of quality culture that includes shared accountability, teamwork, listening, continual improvement, coaching, and integrity.

 

Production Management

 

Moreton agrees. “In my opinion, a quality culture means everyone from the CEO down.  This includes production management and the most junior staff put quality (and patient safety) at the top of their agendas.”

 

Quality requires ‘top-down’ and ‘bottom-up’ approaches. If senior management is not committed/interested, then the junior staff will find it difficult to implement and maintain quality activities.

 

Quality Assurance

 

Similarly, if the junior staff are not properly trained and committed to and interested in quality, then quality assurance will not be properly implemented. “I have seen organizations where the commitment to quality was lacking, and there was, in effect, a lack of a quality culture,” says Moreton.

 

Creating Quality Culture

 

Creating a quality culture starts with the head of the organization, according to Moreton.

 

“The CEO has to be committed in both words and deeds. [The CEO] has to hire people who will help shoulder the burden while maintaining the business. This then goes on down through to the most junior staff.”

 

Performance Feedback

 

“Performance feedback means employees understand how to enforce the rules. There is a line beyond which an individual must not step, because once they have stepped over it, they will be asked to do so again and again—to thine own self be true!,” he says.

 

Communication is key, says Schniepp. “Robust quality cultures have data integrity and welcome feedback from all employees regardless of position within the company. When a company has a poor culture, the communication is top down, and employee opinion and input [are] not valued.”

 

Measuring Quality

 

How does one take stock in the robustness of quality culture in a bio/pharmaceutical company? “There are studies and data that suggest you can measure the quality culture of an organization by looking at the maturity level of the attributes in their quality management system,” says Schniepp. “Certainly, the premise is if you can measure a company’s attributes (CAPA [corrective action and preventive action] system, communications), you can measure the quality culture of an organization.”

 

Regulatory agencies may take the organization’s history into consideration when assessing the effectiveness of a company’s quality practices, especially during an inspection. “How many FDA 483 observations have there been, and how efficiently did they respond and rectify the issues? Undeniably, the FDA inspector will take note of how people are working during an inspection.”

 

Operation Plan

 

In some ways, it all comes down to the inspection process and the FDA inspector,” says Moreton. “[Regulators] want quality (and patient safety) to be taken seriously, and not simply paid lip-service to. They will look at the operation plan to see who makes the decisions affecting quality.”

 

Manufacturing Facility

 

“The general state of the manufacturing facility and the attitude of staff is apparent during an on-site inspections. Consequently, they will analyze how complaints are handled and recall-readiness—how the organization would cope during a recall,” says Moreton.

 

Data Integrity

 

“Regulators have linked the lack of a quality culture with data integrity issues. Further, guidance documents released from the Pharmaceutical Inspection Co-operation Scheme, the UK’s Medicines and Healthcare products Regulatory Agency, the World Health Organization, and FDA all stress the link between a robust quality culture and reliable and consistent data.

 

Employee Feedback

 

One thing they all stress is an open culture that embraces employee feedback and values employee contributions. “Additionally, senior management can often follow the employee’s lead when establishing a culture of quality,” says Schniepp.

 

Poor Quality 

 

Is the investment in creating a company-wide culture of quality worth the time and effort? In fact, it seems the alternative is worse. The repercussions of not having a robust quality culture include higher costs and increased scrutiny by regulators.

 

FDA 483

 

“Ultimately, [the impact] is likely to be financial because there will be FDA 483 observations to remedy. After all, product recalls and the possibility of a consent decree takes time and money. (If people think quality is expensive, try a long FDA 483 list, a product recall, or a consent decree). The company’s stock price will also likely take a hit,” stresses Moreton.

 

“Companies that lack a good quality culture usually have high deviation and FDA investigation rates. For the same reason, this impacts their ability to provide safe and effective medicine to patients. It also costs them more money to perform the investigations making them less efficient,” agrees Schniepp. “In the end, the safety of the patient is what matters most.”

 

About the author

Susan Haigney is the managing editor of Pharmaceutical Technology.

 

Article details

RCA

 

 

 

 

 

Pharmaceutical Technology
Volume 46, Number 5
Pages: 44–45

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Aseptic Technique & Risk Assessment

Q: I work in the quality group for a manufacturer who makes intravenous (IV) injectable drugs using aseptic technique during processing. Recently, the facility has experienced an increase in the number of viable organisms in our environmental monitoring program. Management has asked me to do a risk assessment so we can use our resources effectively. Can you offer some advice on how I should proceed in putting together this assessment?

 

A: Aseptic processing of IV injectable drugs is certainly one of the riskiest manufacturing operations. Your management is correct to be concerned when there is a reported increase in the number of viable organisms in the environment.

 

It is often difficult to determine where a potential microbial ingress is coming from. This is why so much attention is given to monitoring personnel, equipment, air quality, etc., for microbial organisms and identifying and trending what those organisms are and where they are coming from.

 

Aseptic Risk Assessment

 

A risk-based approach to determine the source of the microbial increase is a good start. It is important to remember aseptic does not mean sterile. The objective in aseptic processing is to keep the product, components, and environment as close to sterile as possible. This is accomplished through:

 

  • Proper building, equipment materials, and design
  • Established and validated procedures for cleaning
  • Proper training for personnel
  • Continuous monitoring of personnel and environment

 

All of these aseptic technique examples can ensure the sterile core area and the areas supporting it are properly maintained at all times to avoid product contamination that would impact patient safety.

 

Aseptic Processing

 

Aseptic TechniqueThe first aseptic processing step in risk analysis for your facility is to break down your operations into the various steps. Conduct a safety assessment to determine the highest risk posed to those areas. The highest risk areas tend to be those where personnel are intimately involved. Of these areas, one of the most risky involves the aseptic technique lab and personnel gowning.

 

Proper gowning is crucial to the aseptic filling operation. In some cases, such as compounding pharmacies or manual fills for small clinical trial batches, it may be the only barrier between product and a human. Because we can’t sterilize the human being, we must consider the aseptic solution to make sure they understand proper gowning technique. A safety assessment must show employees fastidiously adhere to process so the patient can be assured the product and aseptic transfer is safe.

 

Aseptic Technique and Aseptic Filling

 

Proper aseptic technique is critical to maintaining the sterile environment where the aseptic product will be filled. The FDA finalized their guidance for industry titled Sterile Drug Products Produced by Aseptic Processing-Current Good Manufacturing Practice.

 

This document placed considerable emphasis on aseptic technique microbiology training and personnel behavior involved in the aseptic fill operation. It is important for the company to continually focus on personnel behavior to avoid complacency and potential product risk. As stated in the guideline:

 

“As operator activities increase in an aseptic processing operation, the risk to finished product sterility also increases. To ensure maintenance of product sterility, it is critical for operators involved in aseptic activities to use aseptic technique at all times.”

 

Aseptic Transfer

 

To establish an operator’s skills to prevent contamination of the culture being maintained , the company should have basic training topics covering personal hygiene. Proper aseptic technique during operations include gowning activities and plating techniques for microbial monitoring. In addition, the company should establish an ongoing training program about aseptic technique microbiology as a way to continually improve the operators’ performance.

 

This training should be documented by the quality department during a safety assessment. Aseptic technique examples that must be reinforced would appear in training records, evaluations of the operator to follow standard operating procedures (SOPs), and monitoring deviations. The concepts set forth in the FDA guideline are also mirrored in European regulations for breaches in aseptic technique during production.

 

Risk Assessment Process

 

One of the more critical areas of your risk assessment is the subject of hazards assessment. For example, proper gowning technique is important to the safety risk assessment. If an operator can’t follow the proper gowning requirements, the product will be at risk the moment the operator enters into the critical manufacturing area. It is interesting to note that in a recent draft guidance issued for compounding facilities, the failure to properly gown is considered to be an insanitary condition.

 

Another discipline that should be considered in your risk assessment plan is cleaning. The cleaning of the line after manufacturing is personnel dependent. If done incorrectly, documentation should include the risk evaluation of product manufactured on the line and the potential for microbial and/or cross contamination. There are many different disinfectant procedures, and it is important that they be executed effectively. Following the ICH Q9 quality risk management framework can help leadership maintain an understanding of an employee’s skills and ability to avoid product contamination.

 

Technical Risk Assessment

 

When establishing your technical risk assessment program, some of the highest risk areas/activities will be those with a high level of human involvement. Assessing those areas first as contributing factors to your environmental problem will help you effectively manage your resources. But be advised that whatever the risk assessment methodology you use to gauge each area/activity of aseptic manufacturing, the dynamic risk must be evaluated and vetted because any area could be the potential source of your microbial problem.

 

About the Article

 

 

Pharmaceutical Technology
Vol. 40, No. 10
Pages: 94, 92

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Emerging Therapies

Click now to listen to Regulatory Compliance Associates’ executive principal consultant, pharma and biologics, Steven J. Lynn, MS, shares his thoughts about emerging therapies, expanding cell and gene therapies on the horizon and how it will affect the industry.

 

 

 

Expanding the Emerging Therapeutic Horizon

Author: Jill Murphy, Editor for BioPharm International

 

 

Drug development is inherently costly and time-intensive, with potential attrition a persistent burden on companies’ finances (1). As companies gain a deeper understanding of cell and molecular biology and seek to develop more complex therapeutics for patient populations, they will also need to be more innovative to ensure commercially viable success is achieved (2).

 

An area that has witnessed significant breakthroughs over recent years has been that of cell and gene therapies. The market for these emerging therapies is projected to grow at a compound annual rate of 22.41% between 2022 and 2030 (3), driven by an expanding pipeline and increasing regulatory approvals.

 

Emerging Therapy Development

 

Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges. Aspects such as demand for accelerated development timelines, advancing technologies, and the growing issue surrounding sustainability are monopolizing the priorities of bio/pharma companies.

 

However, through new opportunities, like allogeneic cell therapy, it is hoped that greater benefits to patients, particularly those in undertreated populations, will be achieved (4).

 

Continued investment in cell and gene therapies

 

Major players in the cell therapy and manufacturing industry are seeing a lot of changes that are heavily impacting the standard processes. The field continues to evolve, and it has been exciting to be a part of the new innovations in the industry, according to Daniel Palmacci, president of Cell & Gene at Lonza.

 

Cell and Gene Development

 

“While there has been a biotech funding slowdown, there remains a healthy pipeline for emerging therapies with nearly 3000 cell and gene products [currently] in development. Commercialization is high on the agenda as more products enter the market,” says Palmacci. “Cell and gene therapies are no longer on the fringe—they are now being used to treat several cancers and rare diseases.”

 

Breakthrough Treatment

 

Steven J. Lynn, MS, executive principal consultant, pharma and biologics at Regulatory Compliance Associates, expands on this and how there is still continued investment in the research and development area to further discover the next breakthrough treatment. “We’ve seen multiple clients either just starting out and needing some upfront advice to the late Phase II company looking to get ready for commercialization,” Lynn says.

 

Facility Automation

 

Tom Fletcher, scientific director at FUJIFILM Irvine Scientific, notes some examples of finding more cost effective, consistent ways to develop therapies, such as converting from adherent cell lines to suspension cell lines, or even finding new ways to use facilities to support automation and retain shipping flexibility.

 

Regulatory Compliance

 

In terms of regulatory and strategy expectations, certain companies are focusing on providing more information on cell and gene development and manufacturing. According to Shankar Iyer, alliance management lead at Pfizer CentreOne, companies feel it is important to reconsider when supply decisions must be made in this industry.

 

Supply Requirements

 

“It used to be that much of the supply of gene therapy products for late-stage clinical and commercial launches was decided at the early stage of clinical development. However, with advancements in biology, engineering, and data sciences, biotechs can establish or negotiate supply requirements in a more agile manner closer to the delivery of gene therapies to clinical subjects and patients,” says Iyer.

 

Addressing new short- and long-term challenges

 

Along with all the excitement that comes with innovations are the hurdles that developers and regulators are persistently working through. Topics such as cost reduction, manufacturing quality and efficiency, and increases in access are continuing to impact cell therapies in the short-term, according to Aaron Dulgar-Tulloch, PhD, technology leader for Genomic Medicine at Cytiva.

 

Proto Oncogenes

 

As for the long-term, however, Dulgar-Tulloch feels that there may be a completely shifted focus. “Long-term, I believe the most pressing challenge facing the cell therapy industry is demonstrating that it can move beyond blood-based cancers and into broader clinical utility in a way that will add differentiated value to the patients, relative to the continuing advancements that are expected from viral vector and nucleic-acid based gene therapies,” he says.

 

Emerging Therapy Commercialization

 

In addition to these points, Palmacci highlights how commercialization is the key challenge when looking from a developer standpoint. “Building specialist skills and regulatory know-how, investing in high-quality raw materials, establishing the right quality systems and analytical processes, and finding a partner with proven GMP [good manufacturing practice] commercialization experience are all critical,” he says.

 

Regulatory Guidance

 

“The ‘capacity crunch’ continues to draw headlines, but building capacity alone is not enough to serve this growing market.” Even with these challenges on the radar, Lynn notes that things are bound to continue changing, as regulators are still learning right along the side of the rest of the industry. However, staying up-to-date on the rapidly changing regulatory guidance across the globe is an ongoing challenge that he feels is never going to go away.

 

The benefits of utilizing allogeneic cell therapies

 

For years, almost all of the most recent cell therapies have used autologous therapies, which are when a patient’s own cells are used to make a therapy that is personalized for the patient. These therapies have been mostly positive for the long-term responses and can avoid issues that can stem from the immune response in patients.

 

Therapeutic Activities

 

A lot of recent developments in this area are focused on making more patient-centric therapies, with an overall outcome to better understand the patient for the most maximized therapeutic outcome. Some pharmaceutical companies have even developed the idea of involving patients in product design from an early stage, exploring their needs, and using their input into target product profiles (2).

 

Allogeneic Therapies

 

Allogeneic cell therapies have been on the rise and look promising, which is where the cells of other healthy donors are used to make a more therapeutic option for multiple individuals at a time. Lynn highlights that some of the benefits of using allogeneic therapies is how they contain cells that are readily available from young and healthy donors who are screened, because they are not coming from a patient who is already sick.

 

Batch Size

 

Usually, allogeneic therapies are grouped together as one, but according to Dan Strange, PhD, CTO at Cellular Origins, there are very notable segmentations. “For example, donor-derived allogeneic therapies are manufactured with processes that still look fairly similar to the manufacturing processes for autologous process (albeit using donor derived material), and with slightly larger batch sizes,” he explains.

 

Single Donor

 

“This approach eliminates a lot of the logistical complexity of the autologous approach, but there are still fundamental limits on how many doses you can make from a single donor—perhaps one batch makes one hundred doses. On the other hand, iPSC-derived allogeneic therapies offer a potentially unlimited supply of cells, but are less well characterized.”

 

Patient Population

 

According to Palmacci, these therapies are considered “off the shelf” models and have a lot of potential for patients. “As they use healthy donor stem cells as starting material, the viability of the cells in the end-product is improved,” he notes. “By enabling the development of many treatments from a single donor, a greater patient population can be treated—improving access and reducing costs.”

 

Autologous Models

 

Although autologous models have been the “safer” option for years for their positive results, Dulgar-Tulloch shares that they can be very complicated to keep up with in comparison to allogeneic models. “Autologous therapies can avoid many of the challenges around donor compatibility and immune rejection because they are created for a specific patient. Because you are developing and treating patients at an individual level, they are also often faster to develop and require less complex clinical trials,” he says.

 

Patient Access

 

“However, this personalized therapy approach is also very difficult to scale from a commercial perspective. It brings increased complexity in manufacturing due to differences in the starting material, higher costs because you can’t benefit from economic scaling, and logistical challenges in increasing patient access.”

 

Population Health

 

As for the future of allogeneic therapies, Lynn is hopeful to see many new approvals for these types of products that just a few years ago would have only been developed for a single patient via an autologous donation. One of the promises of allogeneic therapies is the ability to reach a wider patient population. “Cell and gene therapies can and have helped many patients eradicate their disease,” he says.

 

“If approved allogeneics can hit the market and serve a much bigger patient population, it could be a game changer for many public health issues.” Allogeneic therapies can also expand the access of breakthrough therapies on a worldwide scale by making them more affordable and easier to deliver off-the-shelf, according to Dulgar-Tulloch.

 

3D Manufacturing

 

Palmacci seconds being hopeful for the future for the ultimate benefit of the patients, with an end goal for cell therapies to become so mainstream that they will continue to transform lives. “Greater standardization would help to manage the risk of bringing new therapies to market.

 

Increased automation and digitalization would reduce reliance on manual lab-based manufacturing, and a widespread move from 2D to 3D manufacturing would boost efficiency,” he explains. “There also remains an important role for CDMOs [contract development manufacturing organizations] to help biotechs meet fluctuating demand.”

 

Industry players and allogeneic therapies

 

Some CDMOs look at autologous or allogeneic therapies as major opportunities for their business process. Lynn expands on how the use of allogeneic cells to make therapies does have multiple benefits to the manufacturer and ultimately the patient.

 

“In theory, because allogeneics can aid in getting more cells to produce products for the various therapies, it could be a benefit to CDMOs and CROs because they would be able to produce more product, which leads to less line downtime and more return on the investment,” he says.

 

CDMO and CRO

 

As for Dulgar-Tulloch, this topic is more complex due to the benefits of both kinds of therapies. “If you consider CDMOs and CROs, whose business model is built around service revenue for generating therapeutic doses, both autologous and allogeneic cell therapies are attractive opportunities,” Dulgar-Tulloch highlights.

 

“Autologous might even edge out allogeneic therapy as an opportunity given the sheer scale of manufacturing required to meet the potential patient need. If you look instead at pharmaceutical companies, allogeneic cell therapies are the clear winner from a business opportunity thanks to the increased scalability and decreased costs and logistics.”

 

Cell and Gene Manufacturing

 

Even with the rapid growth of allogeneic cell therapies, Palmacci predicts that autologous cell therapy options will still be here to stay. “Allogeneic cell therapies are easily scalable and do not require multiple manufacturing sites or a decentralized model—one site can serve patients globally,” he shares.

 

“But whether allogeneic or autologous, any therapy that can significantly improve patient outcomes with high efficacy and safety standards is well positioned to generate interest and backing. Both allogeneic and autologous therapies have a role to play within patient treatment, and we do not expect allogeneic therapies to fully replace autologous ones any time soon.”

 

Other up-and-coming therapy developments

 

With the emergence of cell and gene therapy advancements comes other categories of therapeutic options for patients. For example, Palmacci mentions that the rollout of the messenger RNA COVID-19 vaccine has been a testament to the potential of emerging therapies and the speed at which they can transform the outcomes when there is a collective to support their development.

 

Antibody Drug Conjugates (ADCs)

 

Other categories include antibody-drug conjugates (ADCs), cancer vaccines, adoptive cellular therapies, and tumor-infiltrating lymphocytes therapy, according to Lynn, which are more targeted cancer therapies that focus on killing cancer cells. For Fletcher, his first thought in this space is the continued use of exosomes, which are extracellular vesicles that make a powerful vehicle for drug delivery and can be a great tool for addressing different diseases.

 

“Recently, we have learned more about how they operate naturally, which can help us utilize them more effectively,” he adds. Larger patient populations and more polygenic diseases have continued to offer advantages of scale to move therapies out of the lab, and more technology has been trending to leverage multiple or combination platforms, according to Iyer.

 

Mutated Cancer Cells

 

“For example, gene editing with hematopoietic stem cells, viral vector and ADCs as a CAR-T [chimeric antigen receptor T-cell] therapy, and viral and non-viral vector technologies for gene therapy,” he says. “Therapies are starting to move beyond blood-borne cancers and towards treating patients with solid tumors to treat a larger range of cancers.”

 

Strange hopes that both through a combination of manufacturing improvements and therapeutic developments, the industry can bring the cost of cell therapies down to a point where they can be delivered to patients affected by some of the most widespread and devastating diseases of our time.

 

Conclusion

 

Oncology continues to see exciting breakthroughs on the horizon. Dulgar-Tulloch emphasizes these new advancements and what to look forward to in the near future. “In cancer, we continue to see advances in immunotherapies and bispecific antibodies, often in combination with other therapies, with several approvals pending,” he states.

 

“We’re also poised to see two potential blockbuster drugs approved for Alzheimer’s Disease and a vaccine against RSV. With such promise on the horizon, it continues to be an exciting time to work in biotechnology.”

 

Article Details

 

 

BioPharm International
Volume 36, No.5
Pages 10-13, 20

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].